At Bristol Myers Squibb, we are inspired by a single vision-transforming patients’ lives through science. Over the last several decades, our innovative medicines have improved how cancer is treated, making long-term survival a possibility for more patients. Across a broad range of solid tumours and blood disorders, we strive to help more patients with our medicines, scientific discovery and investigational research.Our scientists are exploring new frontiers in the future of personalised medicine, and through new digital platforms, we are converting decades of research and data into insights that sharpen the focus of our work. The breadth of our portfolio, deep scientific expertise, cutting-edge capabilities, and discovery platforms allow us to look at cancer from every angle, targeting the cancer directly and the environment it lives in, and amplifying the body’s ability to fight disease. We are committed to reflecting diverse patient populations in our clinical trials, and are collaborating with partners across the healthcare landscape to increase the speed and efficiency of our research.

As a leader in cancer care, Bristol Myers Squibb is working to empower all people with cancer to have a better future.

Ipsen provides specialty medicines to Healthcare Professionals and their patients suffering from debilitating diseases. At Ipsen, our passion is improving the lives of patients. We do this by working together to build partnerships based on trust and mutual respect with Healthcare Professionals. Ipsen is the Australian affiliate of a global R&D focused pharmaceutical company.

Servier is a privately owned pharmaceutical company, governed by a non-profit foundation that’s committed to therapeutic progress to serve patient needs. Servier has a long-standing commitment to research and development. Servier has significant investment in new products in early development in the areas of Oncology and Haematology with broad research and development platforms in cancer cell apoptosis and immuno-oncology. Servier is proud to support innovative partnering programs with world class institutions including WEHI in Australia to further advance scientific understanding in the area of oncology. Servier Australia’s oncology products include Lonsurf® (trifluridine/tipiracil), Onivyde® (nanoliposomal irinotecan as sucrosofate) and Oncaspar
(pegaspargase).